Skip to main content
. 2020 Nov 10;11:5679. doi: 10.1038/s41467-020-19342-3

Fig. 5. Actionable and oncogenic alterations revealed by clinical sequencing.

Fig. 5

a Fractions of alterations annotated based on their clinical actionability according to PGI in different molecular subtypes of breast cancer. b Distribution of breast cancer samples assigned with the level of the most significant alteration. c Fractions of samples with multiple oncogenic alterations annotated in different molecular subtypes of breast cancer. d Actionable alterations annotated in different molecular subtypes of breast cancer.